@prefix dcterms: . @prefix ns1: . @prefix this: . @prefix sub: . @prefix schema: . @prefix np: . @prefix rdf: . @prefix nt: . @prefix xsd: . @prefix rdfs: . @prefix orcid: . @prefix bl: . @prefix npx: . sub:Head { this: np:hasAssertion sub:assertion; np:hasProvenance sub:provenance; np:hasPublicationInfo sub:pubinfo; a np:Nanopublication . } sub:assertion { bl:category bl:Disease . sub:association rdf:object ; rdf:predicate bl:treats; rdf:subject ; a rdf:Statement; rdfs:label "venlafaxine hydrochloride extended release capsules usp are a serotonin and norepinephrine reuptake inhibitor snri indicated for the treatment of major depressive disorder mdd generalized anxiety disorder gad social anxiety disorder sad panic disorder pd venlafaxine hydrochloride extended release capsules usp are indicated for the treatment of major depressive disorder mdd efficacy was established in three short term 4 8 and 12 weeks and two long term maintenance trials venlafaxine hydrochloride extended release capsules usp are indicated for the treatment of generalized anxiety disorder gad efficacy was established in two 8 week and two 26 week placebo controlled trials venlafaxine hydrochloride extended release capsules usp are indicated for the treatment of social anxiety disorder sad also known as social phobia efficacy was established in four 12 week and one 26 week placebo controlled trials venlafaxine hydrochloride extended release capsules usp are indicated for the treatment of panic disorder pd with or without agoraphobia efficacy was established in two 12 week placebo controlled trials"; bl:association_type bl:ChemicalToDiseaseOrPhenotypicFeatureAssociation; bl:provided_by ; bl:relation schema:TreatmentIndication . bl:category bl:Drug . } sub:provenance { sub:assertion ns1:wasAttributedTo orcid:0000-0002-1468-3557 . } sub:pubinfo { sub:sig npx:hasAlgorithm "RSA"; npx:hasPublicKey "MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB"; npx:hasSignature "jfJW9xt0gDKfNz7qNp/vO81l9cketKsri7eBSzpuz1bG3lUAUBc7fxebaQtPY0BuQIdlNqXnlUSB7fq+Cs/pzBvOZWg6ERQmSAfSYcgVqj9xpKX9LTK1Ln/k2nj+n9GxIKyrGeHw5rCxwyC+VMzrBGwXwHOAz4gro6uZsmrrni0="; npx:hasSignatureTarget this: . this: dcterms:created "2021-06-29T08:11:52.392+02:00"^^xsd:dateTime; dcterms:creator orcid:0000-0002-1468-3557; nt:wasCreatedFromProvenanceTemplate ; nt:wasCreatedFromPubinfoTemplate ; nt:wasCreatedFromTemplate . }